CN Patent

CN112778282B — 一种嘧啶类小分子化合物及其应用

Assigned to Wenzhou Medical University · Expires 2022-07-22 · 4y expired

What this patent protects

本发明公开了一种嘧啶类小分子化合物及其引用，该嘧啶类小分子化合物对PDGFRα和PDGFRβ激酶具有高效的抑制活性，而对其他激酶抑制活性较弱，因而具有很高的选择性，可以作为一种潜在的抗肿瘤或缓解眼科疾病湿性黄斑变性或葡萄膜炎的药物。

USPTO Abstract

本发明公开了一种嘧啶类小分子化合物及其引用，该嘧啶类小分子化合物对PDGFRα和PDGFRβ激酶具有高效的抑制活性，而对其他激酶抑制活性较弱，因而具有很高的选择性，可以作为一种潜在的抗肿瘤或缓解眼科疾病湿性黄斑变性或葡萄膜炎的药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN112778282B
Jurisdiction
CN
Classification
—
Expires
2022-07-22
Drug substance claim
No
Drug product claim
No
Assignee
Wenzhou Medical University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.